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Alpha-fetoprotein (AFP) is a fetal pro-
tein produced in the yolk sac and in the fe-
tal liver. AFP has been implicated in both 
ontogenic and oncogenic growth disor-
ders1. Although the main biologic role of 
AFP during pregnancy remains controver-
sial to this day, AFP has been related to fe-
tal birth defects and tumors1. AFP is rec-
ognized as one of the first tumor markers. 
It was first associated with hepatocellular 
carcinomas and later to germ cell tumors2. 
The autosomal recessive ataxias, in-
cluding ataxia-telangiectasia (AT) and 
ataxia with oculomotor apraxia type 2 
(AOA2), belong to a special group of he-
reditary ataxias with heterogeneous pre-
sentation. Simple laboratory studies, like 
AFP measurement, have been reported to 
be helpful in the differential diagnosis of 
ataxias. 
The purpose of this review is to de-
scribe the association of serum AFP with 
recessive ataxias. We report the clinical 
and laboratory findings of three patients 
with a recessive ataxia profile.
CASES
We identified two patients with clin-
ical and laboratory features of AOA2 
and one patient with AT. Informed and 
written consent were obtained from all 
participants.
Patient 1
A 28-year-old man was seen at the 
neurology department with a twelve-year 
history of progressively worsening balance. 
He had been a normal full-term delivery 
from consanguineous parents. His intelli-
gence was normal. Over the years, he de-
veloped difficulties in writing and speak-
ing. The symptoms progressed slowly over 
the following years.
His neurological examination showed 
muscle strength 5/5, with absent reflex-
es. An ataxic gait with mild enlargement 
of lower-limb basis, considerable stagger-
ing and difficulties with half turn were ob-
served. He was unable to perform tan-
dem walk (heel-to-toe). Finger-nose and 
heel-shin ataxia were evident. He present-
ed clumsiness of fine finger movements. 
Gaze-evoked horizontal nystagmus, ocu-
lar saccadic overshot, ocular apraxia and 
cerebellar dysarthria were also present. Vi-
bration and position senses were also im-
paired. Fundoscopy and visual acuity were 
normal, and there were no telangiectasia.
In order to score the cerebellar dys-
function, we used the International Co-
operative Ataxia Rating Scale (ICARS). It 
consists of four parts: postural and stance 
disorders (7 items; 34 points), limb atax-
ia (7 items; 8 points), dysarthria (2 items; 
8 points), and oculomotor disorders (3 
items; 6 points), with a total of 100 points3. 
The patient reached a score of 47.
Specific laboratory studies were as fol-
lows: albumin: 4.2 g/dl (3.2-5.6 g/dl); total 
cholesterol: 200 mg/dl (<200 mg/dl); AFP: 
9.2 IU/ml (<5.5 IU/ml); vitamin E: 0.5 mg/
dl (0.5-1.8 mg/dl). Routine blood and urine 
testing, echocardiogram and electrocar-
diogram (EKG) were all normal. The au-
diogram showed normal hearing. A genet-
ic study for Friedreich ataxia was negative. 
Brain magnetic resonance imaging 
(MRI) revealed atrophy of the cerebel-
lar hemispheres and vermis, with relative 
preservation of the brainstem and no ab-
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normality in the cerebral hemispheres. Electromyography 
showed severe axonal sensory-motor neuropathy. The ab-
sence of telangiectasias, immunodeficiency or neoplasia, 
an increased AFP levels and the later age of disease onset 
pointed towards the diagnosis of AOA2. This patient will 
be screened for senataxin (SETX) and ataxia telangiecta-
sia mutated (ATM) gene mutation.
Patient 2
Patient 2 was a 20-year-old female. Her conditions of 
birth and early motor and language development were 
normal. Her parents were consanguineous. From the age 
of seventeen years, she began to trip and fall and, by 18 
years, her walking was unsteady, her writing had deterio-
rated and she developed speech slurring. She had normal 
intelligence. Neurological examination showed normal vi-
sual acuity, normal optic fundi and no telangiectasia. Her 
eye movements revealed oculomotor apraxia and square 
wave jerks on pursuit movements with horizontal and 
vertical nystagmus on lateral and vertical gaze respec-
tively. Her speech was characteristic of a mild cerebellar 
dysarthria. Strength was normal and reflexes were absent. 
Pain, light touch, vibration and position sense sensitivity 
were all normal. Tests of coordination revealed moderate 
appendicular and gait ataxia. Her ICARS score was 34. 
EKG and echocardiogram examinations were normal. 
Brain MRI demonstrated marked atrophy of the cerebel-
lar hemispheres and vermis, with relative preservation of 
the brainstem and no abnormality in the cerebral hemi-
spheres.
Laboratory investigations revealed total cholesterol: 
180 mg/dl (<200 mg/dl); albumin: 3.6 g/dl (3.5-4.8 g/dl); 
AFP: 56.25 ng/ml (<10 ng/ml); vitamin E: 1.2 mg/dl (0.5-
1.8 mg/dl). A genetic study for Friedreich ataxia was neg-
ative. Like the first patient, the absence of telangiectasias, 
immunodeficiency or neoplasia, the increased AFP levels 
and the later age at onset of disease all pointed towards 
the diagnosis of AOA2. This patient will also be screened 
for SETX and ATM mutations.
Patient 3
Patient 3 was a nine-year-old boy. His birth and early 
motor and language development were normal. From the 
age of 18 months, he experienced unsteadiness in walking 
with frequent falls. His speech became slurred from the 
age of 7 years, and he developed difficulties in writing. His 
ataxia worsened progressively, but he did not need sup-
port to walk. No cognitive deficits were detected. Dur-
ing the next few years, he presented frequent respirato-
ry infections. 
Physical examination showed his head tilted to the 
right side. Telangiectasia over the bilateral conjunctivae 
was found (Figure). Neurological examination revealed 
oculomotor apraxia. His speech was characteristic of mild 
cerebellar dysarthria. Strength was normal, and reflex-
es were absent. Cervical and limb dystonia were also ob-
served. Tests of coordination revealed moderate appen-
dicular and gait ataxia. His ICARS score was 58. 
On laboratory investigation AFP was elevated to 190.2 
ng/ml (<10 ng/ml), immunoglobulin levels were in the 
normal limits. ATM was detected and the AT diagnosis 
was confirmed. 
DISCUSSION
AT is a rare autosomal recessive disorder character-
ized by ataxia in early childhood, presence of telangiecta-
sias, chromosomal abnormalities, with an increased sen-
sitivity to ionizing radiation, immunodeficiency and ma-
lignancies. Additional findings are oculomotor apraxia, 
dysarthria, peripheral neuropathy and increased AFP lev-
el. AT is caused by mutations in the ataxia telangiectasia 
mutated (ATM) gene4. Recently, Verhagen et al described 
13 adults with variant AT, without ataxia or telangiecta-
sia, but some with hyperkinetic disorders and sensory-
motor neuropathy5. The alpha-fetoprotein levels were el-
evated in all variant cases. Therefore, the diagnosis of AT 
must be considered not only in the classic presentation of 
the disease, but also in chorea, rest tremor and dystonia 
of unknown etiology, even when neuroimaging is normal. 
Our cases may be included in this variant AT group.
Ataxia with oculomotor apraxia type 2 (AOA2) is 
considered one of the most frequent (8%) non-Friedre-
ich autosomal recessive cerebellar ataxias6. It is defined 
genetically by mutations in SETX at 9q34. Features in-
clude onset between ages of 10 and 22 years (age ≤25 
years), elevated serum AFP levels, peripheral neuropa-
thy, occasional oculomotor apraxia and progressive cer-
ebellar ataxia7,8. On the other hand, ataxia with oculomo-
Figure. Characteristic conjunctival telangiectasia observed in
patient 3.
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tor apraxia type 1 (AOA1) has different features such as 
early age at onset, normal serum AFP levels, and hyper-
cholesterolemia and hypoalbuminemia8. In AOA2, ocul-
omotor apraxia is an occasional and inconstant finding, 
while AFP is elevated in almost all patients (even if some-
times it is only in the upper range of normal values). A re-
cent cohort of 90 patients with AOA2 diagnosis showed 
the usefulness of AFP as a good cutoff parameter for se-
lecting patients who should go for sequencing of SETX. 
The same study showed that the likelihood of missing a 
case using this cutoff was 0.23%, while the likelihood that 
a non-Friedreich ataxia, non-ataxia-telangiectasia atax-
ic patient might be affected with AOA2 was 46%9. Oth-
er mutations of SETX have been associated with the au-
tosomal dominant form of juvenile amyotrophic lateral 
sclerosis (ALS4)7,8. 
Beyond the AFP level, when considering neuroimag-
ing findings, both AT and AOA2 present cerebellar at-
rophy. This finding is an important clue for the differen-
tial diagnosis with Friedreich ataxia10. AFP levels are nor-
mal in other recessive ataxias like Friedreich ataxia, ataxia 
with vitamin E deficiency, Abetalipoproteinemia, Charle-
voix-Saguenay spastic ataxia, Refsum disease, Marinesco-
Sjogren ataxia and cerebrotendinous xanthomatosis. The 
laboratory investigative tests on recessive ataxias should 
include: vitamin E, cholesterol, alpha-fetoprotein levels, 
albumin, acanthocytes, phytanic acid, cholestanol and lys-
osomal enzymes11. Numerous autosomal recessive cere-
bellar ataxias remain without clarification of their etiology.
While no treatment for these progressive degenera-
tive ataxias is available, the correct diagnosis is extremely 
important, especially among AT patients, due to the risk 
of cancer and adverse reaction to radiation. High levels 
of alpha-fetoprotein are good markers for suggesting that 
molecular studies on the SETX or ATM gene should be 
carried out. AFP levels should be included in all investiga-
tions of recessive ataxias or early adulthood hyperkinetic 
movement disorders of unknown etiology. 
REFERENCES
1. Mizejewski GJ. Physiology of alpha-fetoprotein as a biomarker for per-
inatal distress: relevance to adverse pregnancy outcome. Exp Biol Med 
(Maywood) 2007;232:993-1004. 
2. Abelev GI, Eraiser TL. Cellular aspects of alpha-fetoprotein reexpression in 
tumors. Semin Cancer Biol 1999;9:95-107.
3. Troillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia 
Rating Scale for pharmacological assessment of the cerebellar syndrome. 
J Neurol Sci 1997;145:205-211. 
4. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA 
Repair 2004;3:1187-1196.
5. Verhagen MM, Abdo WF, Willemsen MA, et al. Clinical spectrum of ataxia-
telangiectasia in adulthood. Neurology 2009;73:430-437.
6. Le Ber I, Bouslam N, Rivaud- Pechoux S, et al. Frequency and phenotypic 
spectrum of ataxia with oculomotor apraxia 2: clinical and genetic study 
in 18 patients. Brain 2004:127:759-767.
7. Criscuolo C, Chessa L, Di Giandomenico S, et al. Ataxia with oculomotor 
apraxia type 2: a clinical, pathologic, and genetic study. Neurology 2006;66: 
1207-1210.
8. Anheim M, Fleury MC, Franques J, et al. Clinical and molecular findings 
of ataxia with oculomotor apraxia type 2 in 4 families. Arch Neurol 2008; 
65:958-962. 
9. Anheim M, Monga B, Fleury M, et al. Ataxia with oculomotor apraxia type 2: 
clinical, biological and genotype/phenotype correlation study of a cohort 
of 90 patients. Brain 2009;132:2688-2698.
10. Fogel B, Perlman S. Clinical features and molecular genetics of autosomal 
recessive cerebellar ataxias. Lancet Neurol 2007;6:245-257.
11. Espinós-Armero C, Gonzales-Cabo P, Palau-Martinez F. Autosomal recessive 
cerebellar ataxias: their classification, genetic features and pathophysiology. 
Rev Neurol 2005;41:409-422. 
